This article is part of the supplement: Abstracts of the 12th Annual SCMR Scientific Sessions – 2009 .

Oral presentation

Cardiac magnetic resonance of targeted annexin-iron oxide labeling detects cardiac cell death in vivo after doxorubicin and myocardial infarction

Rajesh Dash¹, Trevor Chan², Mayumi Yamada², Marietta Paningbatan², Bat-Erdene Myagmar¹, Philip Swigart¹, Paul C Simpson Jr¹ and Phillip C Yang²

¹  San Francisco Veterans Affairs Hospital, San Francisco, CA, USA

²  Stanford University, Stanford, CA, USA

corresponding author email

from 12^th Annual SCMR Scientific Sessions
Orlando, FL, USA. 29 January–1 February 2009

Journal of Cardiovascular Magnetic Resonance 2009, 11(Suppl 1):O8doi:10.1186/1532-429X-11-S1-O8

Published:	28 January 2009

First paragraph (this article has no abstract)

Heart failure from myocardial infarction (MI) or doxorubicin (DOX), used in cancer therapy, is preceded by significant cell apoptosis. Real-time, non-invasive detection of early cardiac apoptosis might impact patient treatment and outcomes. Early apoptosis is detected by Annexin V protein (ANX) binding to externalized membrane phosphatidylserine. To this end, we previously conjugated ANX to superparamagnetic iron oxide (ANX-SPIO). This conjugate specifically binds to early apoptotic cardiac cells in culture and is detectable by in vitro magnetic resonance imaging (MRI).